- Home
- FINW vs IPHA Comparison
FINW vs IPHA Comparison
Compare FINW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINW | IPHA |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1M | 174.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FINW | IPHA |
|---|---|---|
| Price | $18.10 | $1.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $21.67 | $5.00 |
| AVG Volume (30 Days) | 13.9K | ★ 22.5K |
| Earning Date | 01-29-2026 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $80,198,000.00 | $14,839,695.00 |
| Revenue This Year | $72.14 | $22.29 |
| Revenue Next Year | $47.30 | $43.90 |
| P/E Ratio | $16.92 | ★ N/A |
| Revenue Growth | ★ 14.76 | N/A |
| 52 Week Low | $13.49 | $1.47 |
| 52 Week High | $22.49 | $3.51 |
Technical Indicators
Market Signals| Indicator | FINW | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 42.81 |
| Support Level | $17.30 | $1.85 |
| Resistance Level | $18.14 | $1.91 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 43.39 | 11.63 |
Price Performance
Historical ComparisonAbout FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.